These findings demonstrate that routine noninvasive prenatal screening with cfDNA for genetic disorders beyond aneuploidy is possible with high accuracy.”Ģ2q11.2DS had a higher-than-expected prevalence of 1/1,524 pregnancies in this cohort. 1 The authors state that, “this study shows that prenatal screening for 22q11.2DS with SNP-based cfDNA has high sensitivity and specificity in a diverse, real-world population. This publication focuses on the performance of SNP-based NIPT (Panorama) to screen for 22q11.2 deletion syndrome (22q11.2DS) a separate publication will report on test performance for the common aneuploidies. All results included in the analysis were validated with genetic confirmation. The SMART study enrolled more than 20,000 patients at 21 medical centers globally and is the largest prospective non-invasive prenatal testing (NIPT) study ever performed. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the publication of the landmark SMART study in the American Journal of Obstetrics and Gynecology (AJOG), one of the world’s leading Obstetrics and Gynecology medical journals. Schedule Blood Draw (Existing Patients)ĪUSTIN, Texas–( BUSINESS WIRE)– Natera, Inc.Order Tests and Track Status on NateraConnect.Schedule Session with Patient Coordinator.NEVA for Empower – Natera’s Educational Virtual Assistant.Vasistera – Limited Noninvasive Prenatal Testing (NIPT).Panorama – Noninvasive Prenatal Testing (NIPT).Prospera Kidney – Transplant Assessment.Signatera – Residual Disease Test (MRD).
0 Comments
Leave a Reply. |